Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
403
Employees403
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
403
Employees403

NTLA Key Statistics

Market cap
1.38B
Market cap1.38B
Price-Earnings ratio
-2.78
Price-Earnings ratio-2.78
Dividend yield
Dividend yield
Average volume
5.71M
Average volume5.71M
High today
$12.35
High today$12.35
Low today
$11.34
Low today$11.34
Open price
$11.95
Open price$11.95
Volume
5.44M
Volume5.44M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$5.90
52 Week low$5.90

Stock Snapshot

The current Intellia Therapeutics(NTLA) stock price is $12.04, with a market capitalization of 1.38B. The stock trades at a price-to-earnings (P/E) ratio of -2.78.

As of 2026-01-15, Intellia Therapeutics(NTLA) stock has fluctuated between $11.34 and $12.35. The current price stands at $12.04, placing the stock +6.2% above today's low and -2.5% off the high.

The Intellia Therapeutics(NTLA)'s current trading volume is 5.44M, compared to an average daily volume of 5.71M.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.

NTLA News

TipRanks 2d
Cathie Wood Keeps Loading Up on This Biotech Stock — What’s Driving the Steady Buying?

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) continued to buy shares of Intellia Therapeutics (NTLA) on Tuesday, extending a recent buying trend in the...

TipRanks 2d
Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today

20:01 EST Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time, mar...

Simply Wall St 4d
Is Intellia Therapeutics Pricing Reflect Recent Share Rebound Or Long Term Challenges

If you are wondering whether Intellia Therapeutics at around US$10.38 is a bargain or a value trap, you are not alone in asking what the current price really re...

Is Intellia Therapeutics Pricing Reflect Recent Share Rebound Or Long Term Challenges

Analyst ratings

48%

of 27 ratings
Buy
48.1%
Hold
44.4%
Sell
7.4%

More NTLA News

TipRanks 5d
Synopsys, Reddit, Intellia, Symbotic, Seagate Insider Shock

Insiders have been trading these 5 stocks: ((SNPS)), ((RDDT)), ((NTLA)), ((SYM)) and ((STX)). Here is a breakdown of their recent trades and their value. Claim...

TipRanks 6d
Intellia Updates Investors on Nex-Z Trial Safety Hold

Claim 70% Off TipRanks Premium Intellia Therapeutics ( (NTLA) ) just unveiled an update. On January 9, 2026, Intellia Therapeutics updated its corporate prese...

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .